Project Grant SB1HL174252
Award Date
9/17/24
Completion Date
8/31/25
Dollars Obligated
$499K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Austin, TX 78752, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $298,368 to Link Medical LLC to develop a novel device for treating mitral valve regurgitation. The funded project aims to optimize the device design and procedure through bench testing, followed by in vivo feasibility studies. The goal is to create a simpler, more robust, and more effective solution than existing technologies for...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $500,000 in funding to Aventusoft LLC, a small business located in Boca Raton, FL. The goal of this late-stage development project is to advance Aventusoft's non-invasive "HATS-OFF" heart failure monitoring technology towards commercialization. Specifically, the award will enable Aventusoft to: 1) Manufacture the HATS-OFF device with added ECG...
This $2,027,737 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop and validate a machine learning-based software tool for optimizing the placement of the MitraClip device to treat mitral regurgitation. The key products to be delivered under this 30-month award include: 1) A dataset of over 5,000 finite element models of the mitral valve and left ventricle, which will be used to predict mitral regurgitation,...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,024,635 Project Grant to Corvion, Inc. to develop a Totally Implanted Left Ventricular Assist Device (TI-LVAD). The TI-LVAD aims to provide an improved treatment option for the over 6.5 million Americans suffering from heart failure, by reducing complications and enhancing patient quality of life compared to current LVAD devices. The key enabling technology is a...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $413,595 Project Grant to Unandup, LLC, a medical technology firm based in St. Louis, Missouri. The grant will fund the development of a magnetic rotational atherectomy platform to debulk severely calcified coronary lesions and improve percutaneous coronary intervention procedures. Key innovations include the use of magnetic fields to control the atherectomy...
Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...
This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $443,544 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Dasisimulations LLC, a minority-owned small business located in Dublin, Ohio. The grant supports the development and validation of an innovative, AI-driven software platform to automatically perform complex measurements for pre-planning transcatheter aortic valve replacement (TAVR) procedures. The project aims to (1) develop and validate the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $695,865.00 to the University of Pittsburgh to develop an optimized, minimally invasive strategy to treat ischemic cardiomyopathy (ICM). The key products and services to be delivered include: Evaluating the functional, geometric, and histopathologic effects of injecting three different thermoresponsive hydrogel formulations into an ICM...